nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—adrenal gland cancer	0.601	1	CtDrD
Vandetanib—EGFR—adrenal gland cancer	0.248	1	CbGaD
Vandetanib—STK10—renal vein—adrenal gland cancer	0.00782	0.136	CbGeAlD
Vandetanib—STK10—renal artery—adrenal gland cancer	0.00525	0.0917	CbGeAlD
Vandetanib—SRC—adrenal medulla—adrenal gland cancer	0.00392	0.0685	CbGeAlD
Vandetanib—RET—parathyroid gland—adrenal gland cancer	0.00226	0.0395	CbGeAlD
Vandetanib—FMO3—urine—adrenal gland cancer	0.00171	0.0298	CbGeAlD
Vandetanib—Afatinib—EGFR—adrenal gland cancer	0.000991	0.297	CrCbGaD
Vandetanib—Erlotinib—EGFR—adrenal gland cancer	0.0007	0.21	CrCbGaD
Vandetanib—BLK—adrenal gland—adrenal gland cancer	0.000676	0.0118	CbGeAlD
Vandetanib—EPHA6—gonad—adrenal gland cancer	0.000613	0.0107	CbGeAlD
Vandetanib—PLK4—gonad—adrenal gland cancer	0.000606	0.0106	CbGeAlD
Vandetanib—TYRO3—gonad—adrenal gland cancer	0.000569	0.00992	CbGeAlD
Vandetanib—EPHA5—pituitary gland—adrenal gland cancer	0.000555	0.00968	CbGeAlD
Vandetanib—FLT4—adrenal cortex—adrenal gland cancer	0.00053	0.00925	CbGeAlD
Vandetanib—PLK4—adrenal gland—adrenal gland cancer	0.000528	0.00921	CbGeAlD
Vandetanib—VEGFA—adrenal cortex—adrenal gland cancer	0.000526	0.00918	CbGeAlD
Vandetanib—IRAK4—adrenal cortex—adrenal gland cancer	0.000515	0.00899	CbGeAlD
Vandetanib—BMPR1B—adrenal gland—adrenal gland cancer	0.000486	0.00847	CbGeAlD
Vandetanib—FLT3—gonad—adrenal gland cancer	0.000484	0.00844	CbGeAlD
Vandetanib—MKNK1—adrenal cortex—adrenal gland cancer	0.000474	0.00827	CbGeAlD
Vandetanib—STK35—gonad—adrenal gland cancer	0.000474	0.00827	CbGeAlD
Vandetanib—STK35—cardiac atrium—adrenal gland cancer	0.000473	0.00826	CbGeAlD
Vandetanib—AXL—adrenal cortex—adrenal gland cancer	0.000466	0.00814	CbGeAlD
Vandetanib—FMO3—adrenal cortex—adrenal gland cancer	0.000452	0.00789	CbGeAlD
Vandetanib—ABL2—pituitary gland—adrenal gland cancer	0.000451	0.00786	CbGeAlD
Vandetanib—SLK—adrenal cortex—adrenal gland cancer	0.000449	0.00783	CbGeAlD
Vandetanib—CYP3A4—urine—adrenal gland cancer	0.000446	0.00778	CbGeAlD
Vandetanib—Gefitinib—EGFR—adrenal gland cancer	0.000438	0.131	CrCbGaD
Vandetanib—RIPK2—cardiac atrium—adrenal gland cancer	0.000436	0.00761	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—adrenal gland cancer	0.000435	0.00759	CbGeAlD
Vandetanib—Bosutinib—EGFR—adrenal gland cancer	0.000431	0.129	CrCbGaD
Vandetanib—TEK—adrenal cortex—adrenal gland cancer	0.000427	0.00744	CbGeAlD
Vandetanib—RIPK2—pituitary gland—adrenal gland cancer	0.000426	0.00744	CbGeAlD
Vandetanib—VEGFA—pituitary gland—adrenal gland cancer	0.000425	0.00742	CbGeAlD
Vandetanib—FMO1—pituitary gland—adrenal gland cancer	0.000423	0.00738	CbGeAlD
Vandetanib—FLT3—adrenal gland—adrenal gland cancer	0.000422	0.00735	CbGeAlD
Vandetanib—IRAK4—pituitary gland—adrenal gland cancer	0.000416	0.00726	CbGeAlD
Vandetanib—STK35—adrenal gland—adrenal gland cancer	0.000413	0.0072	CbGeAlD
Vandetanib—ABL2—adrenal gland—adrenal gland cancer	0.000402	0.00702	CbGeAlD
Vandetanib—YES1—adrenal cortex—adrenal gland cancer	0.000394	0.00687	CbGeAlD
Vandetanib—EGFR—adrenal gland—adrenal gland cancer	0.000393	0.00685	CbGeAlD
Vandetanib—MKNK1—gonad—adrenal gland cancer	0.000393	0.00685	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—adrenal gland cancer	0.000392	0.00684	CbGeAlD
Vandetanib—AXL—gonad—adrenal gland cancer	0.000386	0.00674	CbGeAlD
Vandetanib—AXL—cardiac atrium—adrenal gland cancer	0.000386	0.00673	CbGeAlD
Vandetanib—MKNK1—pituitary gland—adrenal gland cancer	0.000383	0.00668	CbGeAlD
Vandetanib—FLT4—adrenal gland—adrenal gland cancer	0.000383	0.00668	CbGeAlD
Vandetanib—RIPK2—adrenal gland—adrenal gland cancer	0.000381	0.00664	CbGeAlD
Vandetanib—VEGFA—adrenal gland—adrenal gland cancer	0.00038	0.00663	CbGeAlD
Vandetanib—FGR—pituitary gland—adrenal gland cancer	0.000378	0.0066	CbGeAlD
Vandetanib—RET—pituitary gland—adrenal gland cancer	0.000378	0.0066	CbGeAlD
Vandetanib—FMO1—adrenal gland—adrenal gland cancer	0.000378	0.00659	CbGeAlD
Vandetanib—AXL—pituitary gland—adrenal gland cancer	0.000377	0.00657	CbGeAlD
Vandetanib—IRAK4—adrenal gland—adrenal gland cancer	0.000372	0.00649	CbGeAlD
Vandetanib—SLK—cardiac atrium—adrenal gland cancer	0.000371	0.00648	CbGeAlD
Vandetanib—FMO3—pituitary gland—adrenal gland cancer	0.000365	0.00638	CbGeAlD
Vandetanib—SLK—pituitary gland—adrenal gland cancer	0.000363	0.00633	CbGeAlD
Vandetanib—FYN—cardiac atrium—adrenal gland cancer	0.000361	0.0063	CbGeAlD
Vandetanib—MAP4K5—gonad—adrenal gland cancer	0.000353	0.00616	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—adrenal gland cancer	0.000353	0.00616	CbGeAlD
Vandetanib—TEK—cardiac atrium—adrenal gland cancer	0.000353	0.00616	CbGeAlD
Vandetanib—FYN—pituitary gland—adrenal gland cancer	0.000353	0.00615	CbGeAlD
Vandetanib—KDR—adrenal cortex—adrenal gland cancer	0.000349	0.00608	CbGeAlD
Vandetanib—MAP2K5—adrenal cortex—adrenal gland cancer	0.000349	0.00608	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—adrenal gland cancer	0.000345	0.00601	CbGeAlD
Vandetanib—TEK—pituitary gland—adrenal gland cancer	0.000345	0.00601	CbGeAlD
Vandetanib—MKNK1—adrenal gland—adrenal gland cancer	0.000342	0.00597	CbGeAlD
Vandetanib—FGR—adrenal gland—adrenal gland cancer	0.000338	0.0059	CbGeAlD
Vandetanib—RET—adrenal gland—adrenal gland cancer	0.000338	0.0059	CbGeAlD
Vandetanib—LCK—adrenal gland—adrenal gland cancer	0.000338	0.0059	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—adrenal gland cancer	0.000337	0.00588	CbGeAlD
Vandetanib—AXL—adrenal gland—adrenal gland cancer	0.000337	0.00587	CbGeAlD
Vandetanib—EPHB6—pituitary gland—adrenal gland cancer	0.000329	0.00575	CbGeAlD
Vandetanib—FMO3—adrenal gland—adrenal gland cancer	0.000326	0.0057	CbGeAlD
Vandetanib—YES1—gonad—adrenal gland cancer	0.000326	0.00569	CbGeAlD
Vandetanib—YES1—cardiac atrium—adrenal gland cancer	0.000326	0.00568	CbGeAlD
Vandetanib—SLK—adrenal gland—adrenal gland cancer	0.000324	0.00565	CbGeAlD
Vandetanib—STK10—gonad—adrenal gland cancer	0.000323	0.00564	CbGeAlD
Vandetanib—YES1—pituitary gland—adrenal gland cancer	0.000318	0.00555	CbGeAlD
Vandetanib—FYN—adrenal gland—adrenal gland cancer	0.000315	0.0055	CbGeAlD
Vandetanib—SRC—gonad—adrenal gland cancer	0.000314	0.00548	CbGeAlD
Vandetanib—SRC—cardiac atrium—adrenal gland cancer	0.000314	0.00547	CbGeAlD
Vandetanib—MAP4K5—adrenal gland—adrenal gland cancer	0.000308	0.00537	CbGeAlD
Vandetanib—TEK—adrenal gland—adrenal gland cancer	0.000308	0.00537	CbGeAlD
Vandetanib—PDGFRB—adrenal cortex—adrenal gland cancer	0.000302	0.00526	CbGeAlD
Vandetanib—Afatinib—ABCB1—adrenal gland cancer	0.000301	0.0902	CrCbGaD
Vandetanib—EPHB6—adrenal gland—adrenal gland cancer	0.000294	0.00513	CbGeAlD
Vandetanib—KDR—cardiac atrium—adrenal gland cancer	0.000288	0.00503	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—adrenal gland cancer	0.000288	0.00503	CbGeAlD
Vandetanib—YES1—adrenal gland—adrenal gland cancer	0.000284	0.00496	CbGeAlD
Vandetanib—STK10—adrenal gland—adrenal gland cancer	0.000282	0.00492	CbGeAlD
Vandetanib—KDR—pituitary gland—adrenal gland cancer	0.000282	0.00491	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—adrenal gland cancer	0.000282	0.00491	CbGeAlD
Vandetanib—SRC—adrenal gland—adrenal gland cancer	0.000274	0.00477	CbGeAlD
Vandetanib—ABL1—adrenal cortex—adrenal gland cancer	0.000269	0.00469	CbGeAlD
Vandetanib—KDR—adrenal gland—adrenal gland cancer	0.000252	0.00439	CbGeAlD
Vandetanib—MAP2K5—adrenal gland—adrenal gland cancer	0.000252	0.00439	CbGeAlD
Vandetanib—PDGFRB—gonad—adrenal gland cancer	0.00025	0.00436	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—adrenal gland cancer	0.00025	0.00435	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—adrenal gland cancer	0.000244	0.00425	CbGeAlD
Vandetanib—ABL1—gonad—adrenal gland cancer	0.000223	0.00389	CbGeAlD
Vandetanib—ABL1—cardiac atrium—adrenal gland cancer	0.000222	0.00388	CbGeAlD
Vandetanib—PDGFRB—adrenal gland—adrenal gland cancer	0.000218	0.0038	CbGeAlD
Vandetanib—ABL1—pituitary gland—adrenal gland cancer	0.000217	0.00379	CbGeAlD
Vandetanib—Erlotinib—ABCB1—adrenal gland cancer	0.000213	0.0637	CrCbGaD
Vandetanib—ABCC1—adrenal cortex—adrenal gland cancer	0.000205	0.00357	CbGeAlD
Vandetanib—ABL1—adrenal gland—adrenal gland cancer	0.000194	0.00339	CbGeAlD
Vandetanib—ALB—adrenal gland—adrenal gland cancer	0.000179	0.00313	CbGeAlD
Vandetanib—ABCG2—adrenal cortex—adrenal gland cancer	0.00017	0.00296	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—adrenal gland cancer	0.000169	0.00296	CbGeAlD
Vandetanib—ABCC1—pituitary gland—adrenal gland cancer	0.000166	0.00289	CbGeAlD
Vandetanib—ABCC1—adrenal gland—adrenal gland cancer	0.000148	0.00258	CbGeAlD
Vandetanib—ABCG2—pituitary gland—adrenal gland cancer	0.000137	0.00239	CbGeAlD
Vandetanib—Gefitinib—ABCB1—adrenal gland cancer	0.000133	0.0399	CrCbGaD
Vandetanib—Bosutinib—ABCB1—adrenal gland cancer	0.000131	0.0393	CrCbGaD
Vandetanib—ABCG2—adrenal gland—adrenal gland cancer	0.000122	0.00214	CbGeAlD
Vandetanib—ABL1—Innate Immune System—CTNNB1—adrenal gland cancer	6.07e-06	6.73e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—BAD—adrenal gland cancer	6.04e-06	6.71e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—adrenal gland cancer	6.04e-06	6.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PRKACA—adrenal gland cancer	6.02e-06	6.68e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CTNNB1—adrenal gland cancer	6e-06	6.66e-05	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	5.97e-06	6.63e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—PTGS2—adrenal gland cancer	5.96e-06	6.62e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSHR—adrenal gland cancer	5.96e-06	6.61e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	5.95e-06	6.6e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—CTNNB1—adrenal gland cancer	5.92e-06	6.56e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CTNNB1—adrenal gland cancer	5.92e-06	6.56e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—CTNNB1—adrenal gland cancer	5.9e-06	6.54e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PRKACA—adrenal gland cancer	5.89e-06	6.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—CTNNB1—adrenal gland cancer	5.87e-06	6.51e-05	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	5.86e-06	6.5e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CDC42—adrenal gland cancer	5.85e-06	6.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TERT—adrenal gland cancer	5.85e-06	6.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PRKACA—adrenal gland cancer	5.8e-06	6.43e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—adrenal gland cancer	5.68e-06	6.3e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EGFR—adrenal gland cancer	5.66e-06	6.28e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TERT—adrenal gland cancer	5.64e-06	6.25e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDC42—adrenal gland cancer	5.61e-06	6.22e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MEN1—adrenal gland cancer	5.6e-06	6.21e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PTGS2—adrenal gland cancer	5.6e-06	6.21e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PRKACA—adrenal gland cancer	5.6e-06	6.21e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—POMC—adrenal gland cancer	5.57e-06	6.18e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TERT—adrenal gland cancer	5.57e-06	6.17e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—EGFR—adrenal gland cancer	5.56e-06	6.17e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—BAD—adrenal gland cancer	5.53e-06	6.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—BAD—adrenal gland cancer	5.51e-06	6.11e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—BRAF—adrenal gland cancer	5.5e-06	6.1e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EGFR—adrenal gland cancer	5.47e-06	6.06e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EGFR—adrenal gland cancer	5.44e-06	6.04e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CTNNB1—adrenal gland cancer	5.42e-06	6.02e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—BAD—adrenal gland cancer	5.39e-06	5.98e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EGFR—adrenal gland cancer	5.39e-06	5.98e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—BAD—adrenal gland cancer	5.39e-06	5.98e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EGFR—adrenal gland cancer	5.38e-06	5.97e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TERT—adrenal gland cancer	5.38e-06	5.96e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—BAD—adrenal gland cancer	5.37e-06	5.96e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—BAD—adrenal gland cancer	5.33e-06	5.91e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	5.32e-06	5.9e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—BAD—adrenal gland cancer	5.31e-06	5.89e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—adrenal gland cancer	5.19e-06	5.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CTNNB1—adrenal gland cancer	5.18e-06	5.75e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CDC42—adrenal gland cancer	5.18e-06	5.74e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TERT—adrenal gland cancer	5.17e-06	5.73e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GNAS—adrenal gland cancer	5.15e-06	5.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDC42—adrenal gland cancer	5.1e-06	5.66e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—POMC—adrenal gland cancer	5.1e-06	5.65e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—BAD—adrenal gland cancer	5.09e-06	5.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ABCB1—adrenal gland cancer	5.06e-06	5.61e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—BRAF—adrenal gland cancer	5.03e-06	5.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PRKACA—adrenal gland cancer	5.01e-06	5.56e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—CTNNB1—adrenal gland cancer	5.01e-06	5.55e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—CTNNB1—adrenal gland cancer	5.01e-06	5.55e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDC42—adrenal gland cancer	5e-06	5.54e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CTNNB1—adrenal gland cancer	5e-06	5.54e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—POMC—adrenal gland cancer	4.97e-06	5.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EGFR—adrenal gland cancer	4.93e-06	5.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDC42—adrenal gland cancer	4.92e-06	5.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF2—adrenal gland cancer	4.92e-06	5.46e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—POMC—adrenal gland cancer	4.91e-06	5.45e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—BRAF—adrenal gland cancer	4.9e-06	5.44e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—BAD—adrenal gland cancer	4.9e-06	5.44e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—GNAS—adrenal gland cancer	4.88e-06	5.41e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EGFR—adrenal gland cancer	4.87e-06	5.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TERT—adrenal gland cancer	4.87e-06	5.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—BRAF—adrenal gland cancer	4.85e-06	5.38e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—BAD—adrenal gland cancer	4.84e-06	5.37e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PRKACA—adrenal gland cancer	4.83e-06	5.36e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EGFR—adrenal gland cancer	4.83e-06	5.36e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF2—adrenal gland cancer	4.82e-06	5.34e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EGFR—adrenal gland cancer	4.81e-06	5.33e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—GNAS—adrenal gland cancer	4.78e-06	5.3e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—CTNNB1—adrenal gland cancer	4.76e-06	5.28e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1R—adrenal gland cancer	4.76e-06	5.28e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EGFR—adrenal gland cancer	4.75e-06	5.27e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—adrenal gland cancer	4.75e-06	5.27e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF2—adrenal gland cancer	4.74e-06	5.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—EGFR—adrenal gland cancer	4.74e-06	5.25e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MED12—adrenal gland cancer	4.73e-06	5.25e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—GNAS—adrenal gland cancer	4.7e-06	5.22e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TERT—adrenal gland cancer	4.69e-06	5.21e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—EGFR—adrenal gland cancer	4.69e-06	5.2e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EGFR—adrenal gland cancer	4.69e-06	5.2e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—BAD—adrenal gland cancer	4.68e-06	5.19e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—EGFR—adrenal gland cancer	4.67e-06	5.18e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1R—adrenal gland cancer	4.66e-06	5.17e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—EGFR—adrenal gland cancer	4.64e-06	5.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—BRAF—adrenal gland cancer	4.63e-06	5.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—POMC—adrenal gland cancer	4.63e-06	5.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—BAD—adrenal gland cancer	4.59e-06	5.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1R—adrenal gland cancer	4.59e-06	5.09e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—EGFR—adrenal gland cancer	4.56e-06	5.06e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GNAS—adrenal gland cancer	4.54e-06	5.03e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—adrenal gland cancer	4.5e-06	4.99e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—BAD—adrenal gland cancer	4.49e-06	4.99e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—adrenal gland cancer	4.48e-06	4.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—POMC—adrenal gland cancer	4.46e-06	4.95e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—BRAF—adrenal gland cancer	4.46e-06	4.95e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ABCB1—adrenal gland cancer	4.45e-06	4.94e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—adrenal gland cancer	4.43e-06	4.92e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CTNNB1—adrenal gland cancer	4.42e-06	4.91e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—BAD—adrenal gland cancer	4.42e-06	4.91e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—BRAF—adrenal gland cancer	4.41e-06	4.89e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—POMC—adrenal gland cancer	4.31e-06	4.78e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EGFR—adrenal gland cancer	4.3e-06	4.77e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRKACA—adrenal gland cancer	4.28e-06	4.74e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—BRAF—adrenal gland cancer	4.26e-06	4.72e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDC42—adrenal gland cancer	4.25e-06	4.72e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—BAD—adrenal gland cancer	4.24e-06	4.7e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	4.23e-06	4.69e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TERT—adrenal gland cancer	4.15e-06	4.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF2—adrenal gland cancer	4.1e-06	4.55e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDC42—adrenal gland cancer	4.1e-06	4.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TERT—adrenal gland cancer	4.1e-06	4.54e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—BRAF—adrenal gland cancer	4.09e-06	4.54e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—BAD—adrenal gland cancer	4.08e-06	4.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GNAS—adrenal gland cancer	4.06e-06	4.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TERT—adrenal gland cancer	4.01e-06	4.45e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CTNNB1—adrenal gland cancer	3.98e-06	4.41e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EGFR—adrenal gland cancer	3.97e-06	4.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EGFR—adrenal gland cancer	3.97e-06	4.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1R—adrenal gland cancer	3.96e-06	4.39e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EGFR—adrenal gland cancer	3.96e-06	4.39e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF2—adrenal gland cancer	3.95e-06	4.38e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TERT—adrenal gland cancer	3.95e-06	4.38e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—adrenal gland cancer	3.94e-06	4.37e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—BAD—adrenal gland cancer	3.91e-06	4.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GNAS—adrenal gland cancer	3.91e-06	4.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—BRAF—adrenal gland cancer	3.86e-06	4.28e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1R—adrenal gland cancer	3.82e-06	4.23e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—EGFR—adrenal gland cancer	3.8e-06	4.22e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—EGFR—adrenal gland cancer	3.77e-06	4.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—adrenal gland cancer	3.74e-06	4.15e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—BRAF—adrenal gland cancer	3.72e-06	4.12e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—adrenal gland cancer	3.69e-06	4.09e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CTNNB1—adrenal gland cancer	3.64e-06	4.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDC42—adrenal gland cancer	3.63e-06	4.02e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CTNNB1—adrenal gland cancer	3.63e-06	4.02e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—BAD—adrenal gland cancer	3.61e-06	4.01e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—adrenal gland cancer	3.61e-06	4e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—BAD—adrenal gland cancer	3.56e-06	3.95e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CTNNB1—adrenal gland cancer	3.55e-06	3.94e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CTNNB1—adrenal gland cancer	3.54e-06	3.93e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CTNNB1—adrenal gland cancer	3.53e-06	3.92e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CTNNB1—adrenal gland cancer	3.51e-06	3.89e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—adrenal gland cancer	3.5e-06	3.89e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF2—adrenal gland cancer	3.5e-06	3.88e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CTNNB1—adrenal gland cancer	3.49e-06	3.88e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—BAD—adrenal gland cancer	3.49e-06	3.87e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—POMC—adrenal gland cancer	3.47e-06	3.85e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GNAS—adrenal gland cancer	3.47e-06	3.84e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PRKACA—adrenal gland cancer	3.45e-06	3.83e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—BAD—adrenal gland cancer	3.43e-06	3.81e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	3.43e-06	3.8e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	3.43e-06	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TERT—adrenal gland cancer	3.41e-06	3.78e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1R—adrenal gland cancer	3.38e-06	3.75e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.37e-06	3.74e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—adrenal gland cancer	3.36e-06	3.73e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CTNNB1—adrenal gland cancer	3.35e-06	3.71e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—adrenal gland cancer	3.3e-06	3.67e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—BRAF—adrenal gland cancer	3.29e-06	3.65e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TERT—adrenal gland cancer	3.29e-06	3.65e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—POMC—adrenal gland cancer	3.28e-06	3.64e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—adrenal gland cancer	3.27e-06	3.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—BRAF—adrenal gland cancer	3.24e-06	3.6e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CTNNB1—adrenal gland cancer	3.23e-06	3.58e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—POMC—adrenal gland cancer	3.22e-06	3.57e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CTNNB1—adrenal gland cancer	3.19e-06	3.53e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—BRAF—adrenal gland cancer	3.18e-06	3.52e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—POMC—adrenal gland cancer	3.17e-06	3.51e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—adrenal gland cancer	3.15e-06	3.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—BRAF—adrenal gland cancer	3.13e-06	3.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—adrenal gland cancer	3.12e-06	3.46e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CTNNB1—adrenal gland cancer	3.08e-06	3.41e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—POMC—adrenal gland cancer	3.05e-06	3.39e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CTNNB1—adrenal gland cancer	3.02e-06	3.35e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—adrenal gland cancer	3e-06	3.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BAD—adrenal gland cancer	2.97e-06	3.29e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CTNNB1—adrenal gland cancer	2.96e-06	3.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TERT—adrenal gland cancer	2.91e-06	3.23e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTNNB1—adrenal gland cancer	2.91e-06	3.23e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—adrenal gland cancer	2.88e-06	3.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—adrenal gland cancer	2.87e-06	3.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BAD—adrenal gland cancer	2.86e-06	3.17e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—adrenal gland cancer	2.81e-06	3.12e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—adrenal gland cancer	2.81e-06	3.12e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—adrenal gland cancer	2.8e-06	3.1e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GNAS—adrenal gland cancer	2.8e-06	3.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CTNNB1—adrenal gland cancer	2.79e-06	3.09e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—adrenal gland cancer	2.78e-06	3.08e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—adrenal gland cancer	2.77e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—adrenal gland cancer	2.77e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—adrenal gland cancer	2.75e-06	3.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—POMC—adrenal gland cancer	2.73e-06	3.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BRAF—adrenal gland cancer	2.7e-06	3e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CTNNB1—adrenal gland cancer	2.69e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—adrenal gland cancer	2.66e-06	2.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—adrenal gland cancer	2.65e-06	2.94e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—adrenal gland cancer	2.65e-06	2.93e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—POMC—adrenal gland cancer	2.64e-06	2.92e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—adrenal gland cancer	2.6e-06	2.89e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—adrenal gland cancer	2.58e-06	2.86e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—adrenal gland cancer	2.56e-06	2.84e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MED12—adrenal gland cancer	2.55e-06	2.83e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BAD—adrenal gland cancer	2.53e-06	2.81e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—adrenal gland cancer	2.52e-06	2.8e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—adrenal gland cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—adrenal gland cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—adrenal gland cancer	2.42e-06	2.68e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—adrenal gland cancer	2.38e-06	2.64e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—adrenal gland cancer	2.36e-06	2.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—adrenal gland cancer	2.34e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—adrenal gland cancer	2.34e-06	2.6e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—adrenal gland cancer	2.33e-06	2.59e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—adrenal gland cancer	2.33e-06	2.59e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—adrenal gland cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—adrenal gland cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—adrenal gland cancer	2.29e-06	2.55e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—adrenal gland cancer	2.26e-06	2.51e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—adrenal gland cancer	2.21e-06	2.45e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—adrenal gland cancer	2.13e-06	2.36e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—adrenal gland cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—adrenal gland cancer	2.05e-06	2.27e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—adrenal gland cancer	2.04e-06	2.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—adrenal gland cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—adrenal gland cancer	1.88e-06	2.09e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—adrenal gland cancer	1.88e-06	2.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—adrenal gland cancer	1.88e-06	2.09e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—adrenal gland cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—adrenal gland cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—adrenal gland cancer	1.79e-06	1.99e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—adrenal gland cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—adrenal gland cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—adrenal gland cancer	1.53e-06	1.69e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	1.51e-06	1.68e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—adrenal gland cancer	1.5e-06	1.67e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—adrenal gland cancer	1.5e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—adrenal gland cancer	1.49e-06	1.65e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	1.48e-06	1.64e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—adrenal gland cancer	1.32e-06	1.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—adrenal gland cancer	1.3e-06	1.44e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—adrenal gland cancer	1.25e-06	1.39e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—adrenal gland cancer	1.11e-06	1.23e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.02e-06	1.13e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	8.11e-07	9e-06	CbGpPWpGaD
